Antibodies Archives - WuXi Biology

T-Cell Engagers: Integrated Workflow to Advance TCE Candidates

T-cell engagers (TCEs) are designed to redirect T cells toward tumor cells, offering a highly focused approach to immune-mediated killing....

EpCAM-CD3 BsAb-Encoding mRNA Suppresses Lung Tumors

Bispecific antibodies have emerged as an important modality in oncology, although their broader application can be limited by manufacturing complexity...

In Vivo Evaluation of VEGF-Targeted Bispecific Antibodies

As PD-1/PD-L1 x VEGF-targeted bispecific antibodies gain momentum in oncology, selecting the right preclinical models is becoming increasingly important. These...

PD-1 Blockade with a DLL3 TCE Potentiates Efficacy in SCLC

Small cell lung cancer (SCLC) remains one of the most aggressive and difficult-to-treat cancers, highlighting the ongoing need for new...

R&D Strategies for T Cell Engager Drugs

From hematologic malignancies to solid tumors Introduction: Amid a surge of advancements in immunotherapy, T cell engager (TCE) therapy has...

Antibody-Targeted Precision Medicines

Antibody-targeted therapies—including antibody-drug conjugates (ADCs), antibody-oligonucleotide conjugates (AOCs), and degrader-antibody conjugates (DACs)—are reshaping precision medicine by enabling highly selective delivery...

Solving the Complexities of T Cell Engager Development

T-cell engagers (TCEs) are a class of bispecific antibodies that simultaneously bind tumor cells and T cells, activating T cells...

High-throughput FAMA Assay to Measure Humoral Immunity against Varicella-Zoster Virus

Varicella-zoster virus (VZV) is a highly contagious alpha-herpesvirus that infects more than 90% of people worldwide. The primary infection with...

Efficacy of a TL1A Antibody in an Acute Colitis Mouse Model

Inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn’s disease, is a chronic, immune-mediated disorder characterized by persistent inflammation...

Knowledge Library